Rutgers New Jersey Medical School will be a clinical test site for a study assessing the long term risk of chronic kidney disease in patients who recover from COVID-19. The Multi-Center Assessment of Survivors for Kidney Disease after COVID-19 (MASKeD-COVID) study – conducted by the Division of Nephrology at Mount Sinai – will assess risk in up to 4,000 patients who have recovered from COVID-19 using the artificial-intelligence diagnostic system KidneyIntelX that can incorporate novel protein biomarkers and provide insight into the disease. Researchers will also study patients’ COVID-19 antibody levels over time, which will provide insights into the interaction between immune response and kidney-related complications. Initial research findings are expected to be reported in early 2021. To read the full story.
Recent Posts
- Majority of New Jerseyans Worried About Medical and Health Care Costs.
- NJACTS Community Engagement Core COVID-19 Resources
- With Drowning for Children on the Rise, a Rutgers Heath Expert Discusses Water Safety.
- Researcher Teams Up With Teen Champion Figure Skater to Discover Potential Treatments for Addiction Disorders.
- New Jersey Ranks Near the Bottom on Pay Equity for Mothers.
Categories
- Community (1,934)
- Covid (970)
- CTO Events (1)
- News (2,477)
- Pilots (20)